title: The physician's role in selecting a factor replacement therapy.
abstract: Over the past 20 years, transmissions of human immunodeficiency virus (HIV), hepatitis B virus or hepatitis C virus have been virtually eliminated from plasma-derived or recombinant therapy in the USA, a record that can be largely attributed to the use of effective screening and inactivation technologies for known pathogens. The next significant threat will likely come from the emergence of a new, blood-borne infectious disease, perhaps one transmitted by a non-lipid-enveloped virus or prion, for which current inactivation methods are ineffective. Following the HIV crisis of the 1980s, government, patient advocacy groups, medical and scientific communities and the manufacturers of clotting therapies can learn from the past and approach potential threats from emerging pathogens in a proactive and productive manner. For clinicians, this includes actively engaging patients in a dialogue about all the factors that may influence their choice of clotting factor therapies, including emerging pathogens, patient convenience, consistency and reliability of supply, relative cost/benefit ratios, reimbursement issues (where applicable), patient preference and brand loyalty. It is our obligation as healthcare providers to understand potential risks and help make proactive decisions with our patients, decisions that often must be made in an environment of scientific uncertainty. Threats from infectious agents that were once deemed theoretical can, and often do, ultimately become real, with serious implications for morbidity and mortality.
authors.affiliation: Pediatric Hemophilia and Coagulation Disorders Program, University of Michigan, Women's Hospital, Ann Arbor, 48109, USA. ummdswp@med.umich.edu
authors.forename: S W
authors.initials: SW
authors.lastname: Pipe
mesh_terms: D016913:Blood Component Transfusion / Q000009:adverse effects; D021821:Communicable Diseases, Emerging / Q000517:prevention & control / Q000635:transmission; D018562:Disease Transmission, Infectious; D019983:Guideline Adherence; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D018579:Patient Selection; D010819:Physician's Role; D014481:United States